How interested are pharmaceutical companies in psychedelics? While some are hesitant to even discuss where they stand on this restricted class of drugs, a deal inked last month validates the path of at least one company developing next-generation psychedelics.
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin announces its Q3 results, supported by a conference call. Cash as of December 31, 2021 of CAD$63.6 million.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
Gold, silver rally as traders buy the early dip
Gold and silver futures prices are modestly up in midday U.S. trading Tuesday. Overnight losses were deemed by the precious metals bulls to be a bargain buying opportunity.
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
5 Superb Values In Psychedelic Stocks, 5 Different Reasons To Buy
Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.
Gold price anchored at $1,800
The gold market remain anchored around $1,800 an ounce following stronger than expected labor market data as fewer American workers applied for initial unemployment benefits last week.
Awakn Life Sciences Receives Bold Price Target From H.C. Wainwright
This morning, Awakn Life Sciences Corp. became the latest psychedelic company to obtain coverage under the H.C. Wainwright umbrella.
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.
Amendments To Canada's Special Access Program (SAP) Allows Access To Restricted Psychedelic Drugs. How Will This Affect The Industry?
Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.
Red Light Holland's Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program
Red Light Holland partner, CCrest Laboratories, has been approved by a Health Canada as a supplier of psilocybin for the SAP.
